Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
Julia C. Bennett, Marissa K. Hetrich, Maria Garcia Quesada, Jenna N. Sinkevitch, Maria Deloria Knoll, Daniel R. Feikin, Scott L. Zeger, E. Wangeci Kagucia, Adam L. Cohen, Krow Ampofo, Maria-Cristina de C. Brandileone, Dana Bruden, Romina Camilli, Jesús Castilla, Guanhao Chan, Heather Cook, Jennifer Cornick, Ron Dagan, Tine Dalby, Kostas Danis, Sara de Miguel, Philippe De Wals, Stefanie Desmet, Theano Georgakopoulou, Charlotte Gilkison, Marta Grgič-Vitek, Laura L. Hammitt, Markus Hilty, Pak‐Leung Ho, Sanjay Jayasinghe, James D. Kellner, Jackie Kleynhans, Mirjam J. Knol, Jana Kozáková, Karl G. Kristinsson, Shamez Ladhani, Laura MacDonald, Grant Mackenzie, Lucia Maďarová, Allison McGeer, Jolita Mereckiene, Eva Morfeldt, Tuya Mungun, Carmen Muñoz‐Almagro, J. Pekka Nuorti, Metka Paragi, Tamara Pilishvili, Rodrigo Puentes, Samir K. Saha, Aalisha Sahu Khan, Larisa Savrasova, J. Anthony G. Scott, Anna Skoczyńska, Shigeru Suga, Mark van der Linden, Jennifer R. Verani, Anne von Gottberg, Brita Askeland Winje, İnci Yıldırım, Khalid Zerouali, Kyla Hayford, the PSERENADE Team
Abstract
serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04-0.06) for all ages, 0.05 (0.04-0.05) for <5 years of age, 0.08 (0.06-0.09) for 5-17 years, 0.06 (0.05-0.08) for 18-49 years, 0.06 (0.05-0.07) for 50-64 years, and 0.05 (0.04-0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.